Exo-s-mecamylamine formulation and use in treatment

Abstract

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

We claim: 
     
         1 . A method of treating a medical condition comprising administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition to a subject having a medical condition selected from the group consisting of substance addiction, smoking cessation, weight gain associated with smoking cessation, hypertension, hypertensive crisis, herpes type I and II infection, Tourette's Syndrome, cancer, atherogenic profile, a neuropsychiatric disorder, chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders. 
     
     
         2 . The method according to  claim 1 , wherein said therapeutically effective amount of exo-S-mecamylamine is about 0.001 mg/kg to about 6 mg/kg per day. 
     
     
         3 . The method according to  claim 1 , wherein said therapeutically effective amount of exo-S-mecamylamine is about 0.002 mg/kg to about 3 mg/kg. 
     
     
         4 . The method according to  claim 1 , wherein said therapeutically effective amount of exo-S-mecamylamine is about 0.005 mg/kg to about 2 mg/kg. 
     
     
         5 . The method according to  claim 1 , wherein said therapeutically effective amount of exo-S-mecamylamine is about 0.01 to about 1.5 mg/kg. 
     
     
         6 . The method according to  claim 1 , wherein said therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof is administered by transdermal application, intranasal spray, bronchial inhalation, suppository, intramuscular injection, intravenous injection or orally.